Despite increased regulatory support for pediatric drug development, sponsors still face ethical, economic and practical constraints. Indeed, while children represent about 40% of the world’s population, only 10% of the drugs on the market have been approved for pediatrics. Children are not small adults, and all children are not the same. In particular, children under […]
Read MoreLeveraging PBPK Modeling and Simulation for Neonatal and Infant Drug Development
1 response.
Click here to read/write comments.
Topics:
PBPK Modeling & Simulation